Signet Ring Adenocarcinoma of the Prostate

Giltman, Larry I.

doi:10.1016/s0022-5347(17)54414-6

Cited by 42 publications

(18 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Designation as a signet ring cell carcinoma is restricted to those cases where the signet ring cells make up over 25% of the tumor volume, although a wide range of definitions have been applied. [31][32][33][34][35][36][37][38] Clinically, these tumors are typically of advanced stage at the time of diagnosis. 15,26,36 Serum PSA is usually significantly elevated.…”

Section: Signet Ring Cell Carcinomamentioning

confidence: 99%

Unusual subtypes of prostate cancer

2004

View full text Add to dashboard Cite

The vast majority of prostatic tumors developing in adult males are adenocarcinomas. For the most part, variations in histology have not received specific designations and, from a practical approach, have had any specific prognostic implications handled through application of the Gleason grading system. Nonetheless, some of the adenocarcinoma variants have specific clinical features and differential diagnoses. Furthermore, there has been some controversy regarding the appropriate application of the Gleason grading scheme in these tumors. In addition, there are carcinomas that are in fact not adenocarcinomas and that should be kept as distinct entities. In this paper, the histologic variants of adenocarcinoma are reviewed with emphasis on clinicopathologic features and the clinical relevance of these subtypes. Other carcinomas that occur in the prostate gland are also discussed again with a focus on the clinicopathologic characteristics.

show abstract

Section: Signet Ring Cell Carcinomamentioning

confidence: 99%

Unusual subtypes of prostate cancer

2004

View full text Add to dashboard Cite

show abstract

“…Also, advanced signet ring carcinomas are more extensively invasive and are associated with a poorer prognosis than other histologic subtypes. 23,43 Other, less-common sources of signet ring adenocarcinomas are the breast, 29 bladder, 4,5,12,16 ureter, 7 prostate, 15,39 intestine, 42 ampulla of Vater, 14 endometrium 31 and eccrine sweat glands. 45 Signet ring adenocarcinomas have a propensity to invade lymphatics relatively early and to spread diffusely before giving rise to an obvious mass.…”

Section: Discussionmentioning

confidence: 99%

Signet Ring Adenocarcinoma Metastatic to the Bronchus and Mimicking Goblet Cell Hyperplasia

Dodd¹,

Moore²,

Eedes³

1999

Acta Cytologica

View full text Add to dashboard Cite

“…Signet ring cell carcinoma (SRCC) is commonly seen in organs with mucin-secreting epithelium such as the stomach or colon but can be rarely seen in non-mucin-secreting organs such as the pancreas, breast or prostate 1. Primary SRCC of the prostate is rare and usually presents as an advanced disease.…”

Section: Introductionmentioning

confidence: 99%

Good response of an aggressive rare variant of signet ring cell carcinoma of prostate with hormonal therapy

Tiwari

Nayak²,

Seth

2017

BMJ Case Reports

View full text Add to dashboard Cite

Primary signet ring cell carcinoma (SRCC) of the prostate is a rare entity, characterised by its aggressive nature and dismal prognosis. We report a case of an advanced SRCC of the prostate presenting as a large pelvic mass with obstructive uropathy and rectal involvement managed by complete androgen blockade. At 24 months follow-up, the patient has no evidence of progression or metastasis. Aggressive management with multimodality approach combining surgery, radiation and hormonal ablation can result in long disease-free survival in some patients, despite the aggressive nature of this disease.

show abstract

Signet Ring Adenocarcinoma of the Prostate

Cited by 42 publications

References 4 publications

Unusual subtypes of prostate cancer

Unusual subtypes of prostate cancer

Signet Ring Adenocarcinoma Metastatic to the Bronchus and Mimicking Goblet Cell Hyperplasia

Good response of an aggressive rare variant of signet ring cell carcinoma of prostate with hormonal therapy

Contact Info

Product

Resources

About